Hehe Cao

Hehe Cao

Auto-generated profile, based on publicly available information

Hehe Cao

State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
BHBodan Hu
Bodan Hu
KCKenn Ka-Heng Chik
Kenn Ka-Heng Chik
Jasper Fuk Woo ChanJasper Fuk Woo Chan
Jasper Fuk Woo Chan
JCJianpiao Cai
Jianpiao Cai
HCHehe Cao
Hehe Cao
Shuofeng YuanShuofeng Yuan
Shuofeng Yuan
Enterovirus A71 (EV-A71) infection is a major cause of hand, foot, and mouth disease (HFMD), which may be occasionally associated with severe neurological complications. There is currently a lack of treatment options for EV-A71 infection. The Raf-MEK-ERK signaling pathway, in addition to its critical importance in the regulation of cell growth, differentiation, and survival, has been shown to be essential for virus replication. In this study, we investigated the anti-EV-A71 activity of vemurafenib, a clinically approved B-Raf inhibitor used in the treatment of late-stage melanoma. Vemurafenib exhibits potent anti-EV-A71 effect in cytopathic effect inhibition and viral load reduction assays, with half maximal effective concentration (EC50) at nanomolar concentrations. Mechanistically, vemurafenib interrupts both EV-A71 genome replication and assembly. These findings expand the list of potential antiviral candidates of anti-EV-A71 therapeutics.